CalciMedica, Inc. (CALC)

CalciMedica reported its second-quarter 2025 financial results, collaborated with Telperian to integrate an AI engine for clinical trial analysis, and released its third-quarter 2025 financial results. Oppenheimer reiterated an "Outperform" rating, but the company discontinued its Phase 2 KOURAGE clinical trial due to safety concerns, leading to a stock price decline and a downgrade from H.C. Wainwright. A buy signal was issued from a pivot bottom point, and the stock price saw a slight gain. CALC was trading at $0.600, with its 52-week range spanning from $0.520 to $7.200.

CalciMedica's revenue and product demand are not subject to typical consumer-driven seasonality. Its financial performance is primarily tied to clinical trial progress, regulatory approvals, and potential commercialization. The broader biotech sector can exhibit some seasonal patterns, with the summer months historically challenging for biotech investors. The pharmaceutical industry generally, demand for certain drugs can show seasonality, such as increased demand for flu medication in winter or hay fever medication in spring.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunologic diseases by inhibiting calcium release-activated calcium (CRAC) channels. Their lead product candidate, Auxora™, has shown positive clinical results in trials for various conditions, and they are also advancing CM5480 for pulmonary arterial hypertension.

CalciMedica, Inc. is headquartered in La Jolla, California, United States. While the company conducts clinical trials internationally, specific details regarding a broader international operational or sales geographic footprint are not extensively disclosed.

CalciMedica's brand reputation was negatively impacted by the discontinuation of its Phase 2 KOURAGE clinical trial due to safety concerns, leading to a stock price drop and analyst downgrade. Prior to this, the company had maintained a positive outlook through clinical trial progress, FDA discussions, and preclinical data publication. The broader biopharmaceutical industry has also experienced a decline in public approval.

CalciMedica, Inc. has 42 institutional owners and shareholders who collectively hold 3,623,774 shares. Major institutional shareholders include Deerfield Management Company, L.P., Soleus Capital Management, L.P., and Vanguard Group Inc. Significant individual or private equity firm ownership includes Sanderling Management CO LLC, Alafi Capital Co. LLC, and Deerfield Management Co. LP. Eric Roberts, the Chief Business Officer and Director, made a stock purchase on September 17, 2025.